Thromb Haemost 2007; 97(06): 907-913
DOI: 10.1160/TH06-12-0745
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis

A meta-analysis
Argirios E. Tsantes
1  Laboratory of Hematology & Blood Bank Unit, 'Attikon' General Hospital, School of Medicine, University of Athens, Athens, Greece
,
Georgios K. Nikolopoulos
2  Hellenic Centre for Disease Control and Prevention, Athens, Greece
,
Pantelis G. Bagos
3  Department of Cell Biology and Biophysics, Faculty of Biology, University of Athens, Panepistimiopolis, Athens, Greece
,
Evdoxia Rapti
1  Laboratory of Hematology & Blood Bank Unit, 'Attikon' General Hospital, School of Medicine, University of Athens, Athens, Greece
,
Georgios Mantzios
1  Laboratory of Hematology & Blood Bank Unit, 'Attikon' General Hospital, School of Medicine, University of Athens, Athens, Greece
,
Violeta Kapsimali
4  Immunology-Histocompatibility Department, Evangelismos Hospital, Athens, Greece
,
Anthi Travlou
1  Laboratory of Hematology & Blood Bank Unit, 'Attikon' General Hospital, School of Medicine, University of Athens, Athens, Greece
› Author Affiliations
Further Information

Publication History

Received 31 December 2006

Accepted after revision 19 March 2007

Publication Date:
27 November 2017 (online)

Summary

The effect of the 675 insertion/deletion (4G/5G) polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene on the risk of venous thromboembolism (VTE) remains controversial. In this study, we performed a meta-analysis of published data regarding this issue. A comprehensive electronic search was carried out up until September 2006. A total of 22 articles were included in the analysis that was performed using random effects models. Eighteen papers, concerning patients without another known risk factor, comprised 2,644 cases and 3,739 controls. The alleles contrast (4G vs. 5G allele) yielded a statistically significant odds ratio (OR) of 1.153 (95% confidence interval [CI]: 1.068–1.246). In a sub-analysis of five studies that included 256 cases with another genetic risk factor and 147 controls, the combined per-allele OR was still significant (OR:1.833,95% CI:1.325–2.536). On the contrary, the analysis of five studies regarding cases with a non-genetic risk factor for VTE (antiphospholipid antibody syndrome, Behcet disease) provided insignificant results in all aspects. There was no evidence for heterogeneity and publication bias in all analyses. Based on our findings, the 4G allele appears to increase the risk of venous thrombosis, particularly in subjects with other genetic thrombophilic defects. Recommendation for detection of this polymorphism in evaluating thrombophilia in such patients might be considered.